SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
EPIX MEDICAL, INC.
-----------------------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
-----------------------------------------------------
(Title of Class of Securities)
26881Q101
-----------------------------------------------------
(CUSIP Number)
John Nicholson
Schering Berlin Inc.
340 Changebridge Road
P.O. Box 1000
Montville, NJ 07045
(973)694-4100
-----------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
With a copy to:
Peter S. Wilson, Esq.
Cravath, Swaine & Moore
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019
(212) 474-1000
June 20, 2000
-----------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box. [ ]
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule
240.13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
(Page 1 of 15)
(Exhibit Index is at page 11)
<PAGE>
CUSIP No. 26881Q101
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SCHERING BERLIN VENTURE CORPORATION
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 1,112,075
BENEFICIALLY -------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING -------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 1,112,075
-------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,112,075
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.6%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
-------------------------------------------------------------------------------
(Page 2 of 15)
(Exhibit Index is at page 11)
<PAGE>
CUSIP No. 26881Q101
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SCHERING BERLIN INC.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY -------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH See Items 5(a) and 5(b)
REPORTING -------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
-------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
See Items 5(a) and 5(b)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,112,075 (consisting of possible deemed indirect beneficial ownership
through Schering Berlin Venture Corporation). See Item 5.
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
Certain Shares (See Instructions) [ ]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.6%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO, HC
-------------------------------------------------------------------------------
(Page 3 of 15)
(Exhibit Index is at page 11)
<PAGE>
CUSIP No. 26881Q101
-------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SCHERING AKTIENGESELLSCHAFT
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
-------------------------------------------------------------------------------
3 SEC USE ONLY
-------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
-------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
-------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
-------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY -------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH See Items 5(a) and 5(b)
REPORTING -------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
-------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
See Items 5(a) and 5(b)
-------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,112,075 (consisting of possible deemed indirect beneficial ownership
through Schering Berlin Inc. and Schering Berlin Venture Corporation).
See Item 5.
-------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
Certain Shares (See Instructions) [ ]
-------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.6%
-------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO, HC
-------------------------------------------------------------------------------
(Page 4 of 15)
(Exhibit Index is at page 11)
<PAGE>
Item 1. Security and Issuer
This Schedule 13D relates to the common stock, par value $.01 per
share (the "Common Stock"), of EPIX Medical, Inc., a corporation organized
under the laws of the State of Delaware (the "Company"). The address of the
Company's principal executive offices is 71 Rogers Street, Cambridge,
Massachusetts 02142.
Item 2. Identity and Background
This Schedule 13D is being filed by (i) Schering Berlin Venture
Corporation ("Schering Venture"), a corporation organized under the laws of
the State of Delaware, (ii) Schering Berlin Inc., a corporation organized
under the laws of the State of Delaware ("Schering Berlin"), and (iii)
Schering Aktiengesellschaft, a corporation organized under the laws of the
Federal Republic of Germany ("Schering AG"). Schering Venture, Schering Berlin
and Schering AG are collectively referred to herein as the "Reporting
Persons".
Schering Venture makes equity investments in leading-edge
technologies and technology driven businesses. The address of Schering
Venture's principal business and principal office is 340 Changebridge Road,
Montville, NJ 07045. Schering Venture is a wholly owned subsidiary of Schering
Berlin.
Schering Berlin is a U.S. management holding company for Schering AG
and its principal business is holding stock in and providing services to its
subsidiaries. The address of Schering Berlin's principal business and
principal office is 340 Changebridge Road, Montville, NJ 07045. Schering
Berlin is a wholly owned subsidiary of Schering AG.
Schering AG is a global research-based company engaged in the
discovery, development, manufacture, marketing and sale of pharmaceutical
products. The address of Schering AG's principal business and principal office
is Mullerstrabe 178, 13353 Berlin, Federal Republic of Germany.
The (i) name, (ii) residence or business address, (iii) present
principal occupation or employment and the name, principal business and
address of any corporation or other organization in which such employment is
conducted and (iv) citizenship of each of the executive officers and members
of the Board of Directors, Executive Board or Supervisory Board of each of the
Reporting Persons are set forth on Exhibits 1 through 3 hereto.
None of the Reporting Persons nor, to the knowledge of any Reporting
Person, any natural person named in such Exhibits hereto has, during the last
five years, been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or was a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
which any such Reporting Person or person was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, Federal or state securities laws or finding
any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
The aggregate amount of funds required for the purchase by Schering
Venture of 1,112,075 shares of Common Stock was $20,000,000. Pursuant to a
Stock Purchase Agreement dated as of June 9, 2000, by and between the Company
and Schering Venture (the "Purchase Agreement"), a copy of which is attached
hereto as Exhibit 4, on June 20, 2000, Schering Venture purchased 1,112,075
shares of Common Stock at a price of approximately $17.98 per share. The
$20,000,000 used to purchase the 1,112,075 shares of Common Stock was obtained
by Schering Venture from Schering Berlin.
(Page 5 of 15)
(Exhibit Index is at page 11)
<PAGE>
Item 4. Purpose of Transaction
Schering Venture purchased shares of Common Stock for investment
purposes. In addition, the Company and Schering AG have entered into a
Strategic Collaboration Agreement dated as of June 9, 2000.
The shares of Common Stock held by Schering Venture are subject to
registration rights as described in Section 8 of the Purchase Agreement
attached hereto as Exhibit 4 and incorporated herein by reference. Schering
Venture has agreed, subject to certain exceptions, (i) not to dispose of any
shares of Common Stock for a period of one year after the date of purchase and
(ii) not to acquire any shares of Common Stock for a period of three years
after the date of such agreement. These restrictions are contained in a
Standstill Agreement (the "Standstill Agreement") dated as of June 9, 2000, by
and between Schering Venture and the Company, a copy of which is attached
hereto as Exhibit 5 and incorporated herein by reference. The Reporting
Persons do not have any current plans or proposals which relate to or would
result in:
(a) The acquisition by any person of additional securities of
the Company, or the disposition of any securities of the Company;
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Company;
(c) A sale or transfer of a material amount of assets of the
Company;
(d) Any change in the present board of directors or management
of the Company, including any plans or proposals to change the number or term
of directors or to fill any existing vacancies on the board;
(e) Any material change in the present capitalization or
dividend policy of the Company;
(f) Any other material change in the Company's business or
corporate structure;
(g) Changes in the Company's charter, bylaws or instruments
corresponding thereto or other actions which may impede the acquisition of
control of the Company by any person;
(h) Causing a class of securities of the Company to be delisted
from a national securities exchange or to cease to be quoted in an inter-deal
quotation system of a registered national securities association;
(i) A class of equity securities of the Company becoming
eligible for termination of registration pursuant to Section 12(g)(4) of the
Securities Exchange Act of 1934, as amended; or
(j) Any action similar to any of those enumerated above.
Notwithstanding the foregoing and subject to the Standstill Agreement, the
Reporting Persons may from time to time purchase additional shares of Common
Stock in the open market or otherwise. The timing and amount of any such
purchases will depend on market conditions, business conditions and other
factors. Furthermore, the Reporting Persons, subject to the Standstill
Agreement, reserve the right to reduce their interest in the Company, in whole
or in part, by open market sales of Common Stock or otherwise.
(Page 6 of 15)
(Exhibit Index is at page 11)
<PAGE>
Item 5. Interest in Securities of the Issuer
(a) The Company has informed Schering Venture that there were
12,900,732 shares of Common Stock outstanding as of the close of business on
June 20, 2000, after giving effect to the issuance of the shares of Common
Stock purchased by Schering Venture. Schering Venture owns 1,112,075 shares,
or 8.6%, of the outstanding Common Stock. Schering Berlin, as the owner of
100% of the capital stock of Schering Venture, may be deemed to be the
beneficial owner of the 1,112,075 shares, or 8.6%, of the outstanding Common
Stock held by Schering Venture. Schering AG, as the owner of 100% of the
capital stock of Schering Berlin, may be deemed to be the beneficial owner of
the 1,112,075 shares, or 8.6%, of the outstanding Common Stock held by
Schering Venture. However, this Schedule 13D shall not be construed as an
admission that either Schering Berlin or Schering AG is, for the purposes of
Section 13(d) or 13(g) of the Exchange Act the beneficial owner of any of such
shares of Common Stock owned by Schering Venture.
(b) Schering Venture has the sole power to vote or to direct the vote
and to dispose or to direct the disposition of the 1,112,075 shares of Common
Stock it owns. Schering Venture does not share the power to vote or to direct
the vote or to dispose or to direct the disposition of the 1,112,075 shares of
Common Stock it owns.
By its ownership of 100% of the capital stock of Schering Venture,
Schering Berlin may be deemed to have shared voting or dispositive power with
respect to the 1,112,075 shares of Common Stock owned by Schering Venture. By
its ownership of 100% of the capital stock of Schering Berlin, Schering AG may
be deemed to have shared voting or dispositive power with respect to the
1,112,075 shares of Common Stock owned by Schering Venture.
(c) Other than as disclosed in this Schedule 13D, none of the
Reporting Persons has effected any transaction in the Common Stock in the past
60 days. To the best knowledge of the Reporting Persons, no executive officer
or director of any Reporting Person or member of any Executive or Supervisory
Board, as the case may be, has effected any transaction in the Common Stock
during the past 60 days.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer
The Company and Schering Venture have entered into the Purchase
Agreement, a copy of which is attached hereto as Exhibit 4 and incorporated
herein by reference. The Company and Schering Venture have entered into the
Standstill Agreement, a copy of which is attached hereto as Exhibit 5 and have
incorporated herein by reference.
Item 7. Material to Be Filed as Exhibits
Exhibit 1 Information with respect to the Directors and Executive
Officers of Schering Venture.
Exhibit 2 Information with respect to the Directors and Executive
Officers of Schering Berlin.
Exhibit 3 Information with respect to Members of the Executive Board and
Supervisory Board of Schering AG.
Exhibit 4 Stock Purchase Agreement dated as of June 9, 2000, by and
between the Company and Schering Venture.
Exhibit 5 Standstill Agreement dated as of June 9, 2000, by and between
Schering Venture and the Company.
(Page 7 of 15)
(Exhibit Index is at page 11)
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: June 29, 2000
SCHERING BERLIN VENTURE CORPORATION,
by /s/ Robert A. Chabora
------------------------------
Name: Robert A. Chabora
Title: Secretary
(Page 8 of 15)
(Exhibit Index is at page 11)
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: June 29, 2000
SCHERING BERLIN INC.,
by /s/ Robert A. Chabora
------------------------------
Name: Robert A. Chabora
Title: Secretary
(Page 9 of 15)
(Exhibit Index is at page 11)
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: June 30, 2000
SCHERING AKTIENGESELLSCHAFT,
by /s/ Frank Alburg
------------------------------
Name: Frank Alburg
Title: Head of Group Finance
by /s/ Bernd Vogt
------------------------------
Name: Bernd Vogt
Title: Legal Department
(Page 10 of 15)
(Exhibit Index is at page 11)
<PAGE>
EXHIBIT INDEX
Exhibit No. Description
Exhibit 1 Information with respect to the Directors and Executive
Officers of Schering Venture.
Exhibit 2 Information with respect to the Directors and Executive
Officers of Schering Berlin.
Exhibit 3 Information with respect to Members of the Executive
Committee and Supervisory Board of Schering AG.
Exhibit 4 Stock Purchase Agreement dated as of June 9, 2000, by and
between the Company and Schering.
Exhibit 5 Standstill Agreement dated as of June 9, 2000 by and between
Schering Venture and the Company.
(Page 11 of 15)
(Exhibit Index is at page 11)
<PAGE>
Exhibit 1
Directors and Executive Officers of
Schering Berlin Venture Corporation
The following table sets forth the name, business address, present
principal occupation or employment of each of the directors and executive
officers of Schering Berlin Venture Corporation. Unless otherwise indicated,
the business address of each individual listed below is Schering Berlin
Venture Corporation, 340 Changebridge Road, P.O. Box 1000, Montville, NJ
07045-1000, and the position listed is with Schering Berlin Venture
Corporation. All the directors and officers listed below are citizens of the
United States of America, except for Lutz Lingnau who is a citizen of the
Federal Republic of Germany. Directors are indicated by an asterisk.
Present Principal Occupation
Name and Business Address or Employment
------------------------------------ ------------------------------
Lutz Lingnau* Chairman; President & Chief Executive
Officer, Schering Berlin Inc.
Robert A. Chabora* Secretary; Secretary, Vice President-
Law and General Counsel, Schering
Berlin Inc.
John Nicholson* Treasurer; Treasurer, Schering Berlin
Inc.
Dr. Leslie Brown President.
(Page 12 of 15)
(Exhibit Index is at page 11)
<PAGE>
Exhibit 2
Directors and Executive Officers of
Schering Berlin Inc.
The following table sets forth the name, business address,
present principal occupation or employment of each of the directors and
executive officers of Schering Berlin Inc. Unless otherwise indicated, the
business address of each individual listed below is Schering Berlin Inc., 340
Changebridge Road, P.O. Box 1000, Montville, NJ 07045-1000, and the position
listed is with Schering Berlin Inc. All the directors and officers listed
below are citizens of the United States of America, except for Lutz Lingnau,
Wolfgang Kunze, Dr. Hubertus Erlen, Dr. Ulrich Kostlin, Dr. Klaus Pohle and
Prof. Gunter Stock, each of whom is a citizen of the Federal Republic of
Germany. Directors are indicated by an asterisk.
Present Principal Occupation
Name and Business Address or Employment
------------------------------------ ------------------------------
Lutz Lingnau* President & Chief Executive Officer.
Robert A. Chabora Secretary, Vice President-Law and
General Counsel.
Wolfgang Kunze* Vice President-Finance & Chief
Financial Officer.
Robert C. Milos Assistant Treasurer.
Berlex Laboratories Inc.
300 Fairfield Road
Wayne, NJ 07047
John Nicholson Treasurer.
John F. Rotondo Assistant Secretary and Vice President.
Berlex Laboratories Inc.
300 Fairfield Road
Wayne, NJ 07047
Dr. Hubertus Erlen* Chairman, Board of Directors.
Schering AG
13353 Berlin
Dr. Ulrich Kostlin* Member, Executive Board, Schering
Schering AG AG.
13353 Berlin
George G. Montgomery, Jr.* Advisor Director, Hambrecht & Quist
Hambrecht & Quist LLC LLC.
1 Bush Street
San Francisco, CA 94104
Dr. Klaus Pohle* Vice Chairman, Executive Board and
Schering AG Chief Financial Officer, Schering AG.
13353 Berlin
Prof. Gunter Stock* Member, Executive Board, Schering
Schering AG AG.
13353 Berlin
(Page 13 of 15)
(Exhibit Index is at page 11)
<PAGE>
Exhibit 3
Members of the Executive Board and
Supervisory Board of Schering Aktiengesellschaft
The following table sets forth the name, business address,
present principal occupation or employment of each of the members of the
executive committee and supervisory board of Schering AG. Unless otherwise
indicated, the business address of each individual listed below is Schering
AG, Mullerstra e 178, 13353 Berlin, Germany, and the position listed is with
Schering AG. All the directors and officers listed below are citizens of the
Federal Republic of Germany, except for Dr. Giuseppe Vita, who is a citizen of
Italy, Prof. Dr. Piet Borst, who is a citizen of The Netherlands, and Prof.
John A. Dormandy, who is a citizen of the United Kingdom.
Present Principal Occupation
Name and Business Address or Employment
------------------------------------ ------------------------------
Dr. Giuseppe Vita Chairman, Executive Board.
Dr. Klaus Pohle Vice Chairman, Executive Board;
Chief Financial Officer.
Dr. Hubertus Erlen Member, Executive Board.
Dr. Ulrich Kostlin Member, Executive Board.
Prof. Gunter Stock Member, Executive Board.
Klaus Subjetzki Chairman, Supervisory Board;
BHF-BANK Chairman, Supervisory Boards BHF-
Bockenheimer Landstr. 10 BANK.
60323 Frankfurt/Main
Jurgen Wingefeld Vice Chairman, Supervisory Board;
Lausitzer und Mitteldeutsche Director for General Personnel and
Bergbau mbH Social Services, Lausitzer und
10100 Berlin Mittledeutsche Bergbau
Dr. rec. oec. Karl-Hermann Baumann Member, Supervisory Board;
Siemens AG Chairman, Supervisory Board,
80333 Munchen Siemens AG.
Prof. Dr. Piet Borst Member, Supervisory Board;
The Netherlands Cancer Institute Professor of Clinical
Plesmanlaan 121 Biochemistry, University of
NL-1066 CX Amsterdam Amsterdam
Norbert Deutschmann Member, Supervisory Board;
Chairman, Wedding Works Council.
Prof. John A. Dormandy Member, Supervisory Board;
St. George's Hospital Professor of Vascular Sciences,
London SW 17 0QT University of London.
Dr. rer. pol. Reiner Hagemann Member, Supervisory Board;
Allianz Versicherungs-AG Chairman, Executive Board, Allianz
Koniginstra ezg Verischerungs-AG.
80802 Munchen
Johannes Heitbaum Member, Supervisory Board,
Schering AG Bergkamen Vice Chairman, Bergkamen Works
59192 Bergkamen Council.
(Page 14 of 15)
(Exhibit Index is at page 11)
<PAGE>
Present Principal Occupation
Name and Business Address or Employment
------------------------------------ ------------------------------
Dr. h.c. Martin Kohlhaussen Member, Supervisory Board;
Commerzbank AG Spokesman, Executive Board,
60261 Frankfurt/Main Commerzbank AG.
Dr. rev. pol. Jurgen Krumnow Member, Supervisory Board; Member,
Deutsche Bank AG Advisory Group, Deutsche Bank AG.
60325 Frankfurt/Main
Dr. med. Hans-Peter Niendorf Member, Supervisory Board; Head of
Clinical Development Diagnostics,
Schering AG.
Hans-Jurgen Scheel Member, Supervisory Board; Vice
Chairman, Wedding Works Council.
Gunter Schmitt Member, Supervisory Board; Member,
Wedding Works Council.
Dr. rer. oec. Ulrich Sommer Member, Supervisory Board;
Chairman, Schering Wedding
Works Chapter of the VAA Professional
and Management Union for the
Chemical Industry, Berlin.
Heinz Georg Webers Member, Supervisory Board;
Schering AG Chairman, Central Works Council;
53132 Bergkamen Chairman, Bergkamen Works
Council.
Prof. Dr. Meinhart H. Zenk Member, Supervisory Board;
Biozentrum Universitat Professor, Pharmaceutical Biology,
Halle Weinbergweg 22 Martin-Luther University, Halle-
06120 Halle/Saale Wittenberg.
(Page 15 of 15)
(Exhibit Index is at page 11)
